New York State Common Retirement Fund Has $1.75 Million Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

New York State Common Retirement Fund boosted its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 24.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 220,627 shares of the company's stock after buying an additional 42,909 shares during the quarter. New York State Common Retirement Fund owned 0.07% of Amneal Pharmaceuticals worth $1,747,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. JPMorgan Chase & Co. grew its holdings in shares of Amneal Pharmaceuticals by 149.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,297,094 shares of the company's stock worth $10,792,000 after acquiring an additional 777,568 shares during the last quarter. Geode Capital Management LLC increased its stake in Amneal Pharmaceuticals by 11.1% in the 3rd quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company's stock worth $31,511,000 after purchasing an additional 378,136 shares in the last quarter. Polar Asset Management Partners Inc. raised its holdings in Amneal Pharmaceuticals by 122.5% during the 3rd quarter. Polar Asset Management Partners Inc. now owns 393,000 shares of the company's stock worth $3,270,000 after buying an additional 216,400 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Amneal Pharmaceuticals by 16.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,404,883 shares of the company's stock valued at $11,689,000 after buying an additional 202,863 shares in the last quarter. Finally, Barclays PLC boosted its holdings in shares of Amneal Pharmaceuticals by 134.1% in the third quarter. Barclays PLC now owns 296,384 shares of the company's stock worth $2,466,000 after buying an additional 169,756 shares during the period. 31.82% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analysts Set New Price Targets

A number of equities analysts recently commented on AMRX shares. Piper Sandler raised their price objective on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an "overweight" rating in a research note on Monday, November 11th. StockNews.com cut Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Thursday, December 19th. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and upped their price target for the company from $9.00 to $12.00 in a research report on Monday, February 24th. Finally, Barclays increased their price objective on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a research note on Monday. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $10.80.

Insider Buying and Selling

In other Amneal Pharmaceuticals news, Director Gautam Patel sold 62,590 shares of the stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $8.01, for a total transaction of $501,345.90. Following the transaction, the director now directly owns 1,968,886 shares of the company's stock, valued at $15,770,776.86. This represents a 3.08 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Over the last quarter, insiders have sold 240,000 shares of company stock worth $2,004,000. Insiders own 26.56% of the company's stock.

Amneal Pharmaceuticals Stock Down 1.6 %

Shares of NASDAQ:AMRX traded down $0.15 during trading on Thursday, reaching $8.83. 1,538,898 shares of the company traded hands, compared to its average volume of 1,385,837. Amneal Pharmaceuticals, Inc. has a 1-year low of $5.18 and a 1-year high of $9.48. The firm has a market cap of $2.73 billion, a P/E ratio of -12.98 and a beta of 1.10. The firm has a fifty day simple moving average of $8.16 and a 200 day simple moving average of $8.34.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its quarterly earnings data on Friday, February 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. The firm had revenue of $730.52 million for the quarter, compared to analyst estimates of $708.21 million. During the same period in the previous year, the business posted $0.14 EPS. As a group, research analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.